Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT

Background: Combination antiretroviral therapy (cART) is the standard for human immunodeficiency virus (HIV) infection treatment but can result in metabolic abnormalities, such as insulin resistance, dyslipidaemia and lipodystrophy, which can increase the risk of cardiovascular disease. Objective: T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sudeep Pushpakom, Ruwanthi Kolamunnage-Dona, Claire Taylor, Terry Foster, Catherine Spowart, Marta Garcia-Finana, Graham J Kemp, Thomas Jaki, Saye Khoo, Paula Williamson, Munir Pirmohamed
Formato: Artigo
Idioma:Inglês
Publicado em: NIHR Journals Library 2019-07-01
Colecção:Efficacy and Mechanism Evaluation
Assuntos:
hiv
antiretroviral drugs
insulin resistance
metabolic disease
telmisartan
drug safety
adipose tissue
adipokines
lipodystrophy
fat redistribution
cardiovascular disease
adaptive trials
Acesso em linha:https://doi.org/10.3310/eme06060
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados